virotherapy in cancer

new cancer therapies with novel mechanisms and functions are needed to treat patients with different cancers. virotherapy is a good scenario for such treatment. the advantages of virotherapy include the potential lack of cross resistance with standard therapies and the ability to cause tumor destruction by numerous mechanisms. oncolytic virus not only possesses unique mechanisms of action that are distinct from other treatment modalities, its self-perpetuating nature provides an ideal platform for therapeutic transgenic insertion. in this review article, a variety of oncolytic viruses in cancer gene therapy will be described. please cite this article as: motalleb gh. virotherapy in cancer. iran j cancer prev. 2013; 6(2):101-107. references 1. pandha h, melcher a, harrington k, vile r. oncolytic viruses: time to compare, contrast, and combine? mol ther. 2009; 17(6):934-5. 2. motalleb g, fauziah o, aini i, asmah r. dissemination of newcastle disease virus (ndv-af2240) in liver during intratumoral injection of 4t1 xenotransplant breast cancer in balb/c mice. the cell. 2009; 11(3):303-310. 3. motalleb g, fauziah o, aini i, asmah r. transmission electron microscopy and confocal laser scanning microscopy of newcastle disease virus (ndv2240) in lung during intratumoral injection in 4t1 breast cancer in balb/c mice. malaysian j of microscopy.2009; 5:42-53. 4. ottolino-perry k, diallo js, lichty bd, bell jc, mccart ja. intelligent design: combination therapy with oncolytic viruses. mol ther. 2010; 18(2):251-63. 5. le doux jm. methods in molecular biology, vol 433 (1). production and in vivo applications of gene transfer vectors. humana press, totowa; 2008: 243-4.  6. king rjb, robins mw. cancer biology. pearson education limited. england; 2006:259-60. 7. schulz wa. molecular biology of human cancers. springer; 2005:464. 8. william j, zhou q. viral vectors for cancer gene therapy: viral dissemination and tumor targeting. curr gene ther. 2005; 5:133-42. 9. othman f, ideris a, motalleb gh, eshak zb, rahmat a. oncolytic effect of newcastle disease virus af2240 strain on the mcf-7 breast cancer cell line .cell j.2012;12(1): 17-24. 10. cripe tp, wang py, marcato p, mahller yy, lee pwk. targeting cancer-initiating cells with oncolytic viruses. mol ther. 2009; 17(10):1677-82. 11. norman kl, hirasawa k, yang ad, shields ma, lee pw. reovirus oncolysis: the ras/raigef/p38 pathway dicates host cell permissiveness to reovirus infection. proc natl acad sci. 2004; 101(30):11099-104. 12. marcato p, schmulevitz m, lee pw. connecting reovirus on-colysis and ras signaling. cell cycle. 2005; 4(4): 556-9. 13. hirasawa k, nishikawa sg, norman kl, coffey mc, thomp-son bg, yoon cs, et al. systemic reovirus therapy of metastatic cancer in immune-competent mice.  cancer res. 2003; 63(2): 348-53. 14. etoh t, himeno y, matsumoto t, aramaki m, kawano k, nishizono a, et al. oncolytic viral therapy for human pan-creatic cancer cells by reovirus. clin cancer res. 2003; 9(3):1218-23. 15. stanford mm, barrett jw, nazarian sh, werden s, mcfadden g. oncolytic virotherapy synergism with signaling inhibitors:rapamycin increases myxoma virus tropism for human tumor cells.  j virol. 2007; 81(3):1251-60. 16. lun x, yang w, alain t, shi zq, muzik h, barret jw, et al. myxoma virus is a novel oncolytic virus with significant antitu-mor activity against experimental human gliomas.  cancer res. 2005; 65(21): 9982-90. 17. brandenburger a, legendre d, avalosse b, rommelaere j. ns-1 and ns-2 proteins may act synergistically in the cyto-pathogenicity of parvovirus mvmp.  virology. 1990; 174(2):576-84. 18. di piazza m, mader c, geletneky k, herrero y, calle m, weber e, et al. cytosolic activation of cathepsins mediates parvovirus h-1-induced killing of cisplatin and trail-resistant glioma cells. j virol. 2007; 81(8): 4186-98. 19. herrero ycm, cornelis jj, herold-mende c, rommelaere j, schlehofer jr, geletneky k. parvovirus h-1 infection of human glioma cells leads to complete viral replication and effi-cient cell killing.  int j cancer.  2004; 109(1): 76-84. 20. geletneky k, herrero ycm, rommelaere j, schlehofer jr. oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review.  j vet med.  2005; 52(7-8):327-30. 21. smith rr, huebner rj, rowe wp, schatten we, thomas lb. studies on the use of viruses in the treatment of carcinoma of the cervix.  cancer. 1956; 9(6): 1211-18. 22. cervantes-garcía d, ortiz-lópez r, mayek-pérez n, rojas-martínez a. oncolytic virotherapy. annals of hepatol. 2008; 7(1):34-45.   23. donofrio g, caviran s, van santen v, flammini cf. potential secondary pathogenic role for bovine herpesvirus 4.  j clin microbiol. 2005; 43(7): 3421-6. 24. gillet l, dewals b, farnir f, de leval l, vanderplasschen a. bovine herpesvirus 4 induces apoptosis of human carcinoma cell lines  in vitro and in vivo .  cancer res.  2005; 65(20): 9463-72. 25. shafren dr, dorahy dj, ingham ra, burns gf, barry rd. coxsackievirus a21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry.  j virol. 1997; 71(6): 4736-43. 26. shafren dr, au gg, nguyen t, newcombe ng, haley es, beagley l, et al. systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21.  clin cancer res. 2004; 10(1): 53-60. 27. david k, robert lm, zwiebel j. replication-selective virotherapy for cancer: biological principles, risk management and future directions. nature med. 2001; 7(7):781-7. 28. flanagan ad, love r, tesar w. propagation of newcastle disease virus in ehrlich ascites cells in vitro and in vivo . proc soc exp biol med. 1995; 90:82-6. 29. fauziah o, aini i, asmah r, omar ar, abdul-manaf a, jafri m. proceedings yemeni scietific conference: oct 11-13 2004; sanaa. yemen. replication of newcastle disease virus in the breast cancer cell lines. 30. lorence rm, katubig bb, reichard kw.complete regression of human fibrosarcoma xenografts after local newcastle disease virus therapy. cancer res. 1994;54:6017-21. 31. mullen jt, tanabe kk. viral oncolysis. oncologist.2002; 7:106-119. 32. rommelaere j, cornelis jj. antineoplastic activity of parvoviruses. j virol methods.1991; 33:233-51. 33. olijslagers s, dege ay, dinsart c. potentiation of a recombinant oncolytic parvovirus by expression of apoptin. cancer gene ther.2001; 8:958-65. 34. madigan mt, martinko jm, parker j. brock biology of microorganisms. 9th edn. upper saddal river, nj:prentice-hall, inc.;2000. 35. coffey mc, strong je, forsyth pa, lee pw. reovirus therapy of tumors with activated ras pathway. science.1998; 282:1332-4. 36. strong je, coffey mc, tang d, sabinin p, lee pw. the molecular basis of viral oncolysis: usurpation of the ras signaling pathway by reovirus. embo j.1998; 17:3351-62. 37. kinzler kw, vogelstein b. lessons from hereditary colorectal cancer. cell.1996; 87:159-70. 38. norman kl, coffey mc, hirasawa k. reovirus oncolysis of human breast cancer. hum gene ther.2002; 13:641-52. 39. hirasawa k, nishikawa sg, norman kl. systemic reovirus therapy of metastatic cancer in immune-compe-tent mice. cancer res.2003; 63:348-53. 40. paiva lr, silva hs, ferreira hs, martins ml. multiscale model for the effects of adaptive immunity suppression on the viral therapy of cancer. phys biol. 2013; 10(2):5005. everts b, van der poel hg. replication-selective oncolytic viruses in the treatment of  cancer. cancer gene ther. 2005; 12(2):141-61.